FSTL3 and cancer: Experimental overexpression of FSTL3 in murine ovarian cancer cells changed the TME by promoting cancer cell EMT, increasing stromal fibrosis, reducing immunocyte recruitment, and promoting T cell exhaustion, which we speculate contributed to the induced resistance to PPC combination immunotherapy.